Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
纯化方法
This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
免疫原
This Osteocalcin antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 2-32 amino acids from the N-terminal region of human Osteocalcin.
BGP antibody, OC antibody, OCN antibody, Bglap1 antibody, Bglap2 antibody, OG1 antibody, mOC-A antibody, Bgp antibody, Bgpr antibody, Bgpra antibody, bgp antibody, LOC792433 antibody, ocn antibody, GLA antibody, BGLAP antibody, PMF1 antibody, bone gamma-carboxyglutamate protein antibody, bone gamma carboxyglutamate protein antibody, bone gamma-carboxyglutamate protein S homeolog antibody, bone gamma-carboxyglutamate (gla) protein antibody, osteocalcin antibody, polyamine-modulated factor 1 antibody, BGLAP antibody, Bglap antibody, bglap.S antibody, bglap antibody, ocn antibody, LOC100529177 antibody, LOC100146589 antibody
背景
Prior to the formation of calcified bone, noncollagenous proteins form in the extracellular bone matrix. Gamma-carboxyglutamic acid residues are formed by vitamin K, vitamin-D regulated calcium binding proteins containing residues of Gla. These residues are essential for the binding of calcium and constitue 1-2 % of total bone protein. Osteocalcin itself binds strongly to apatite and calcium. Production of osteocalcin is expressed late in normal bone development and is characteristic of mature osteoblasts. Regular osteocalcin production has been shown to be linked to the p53 tumor suppressor gene. The p53 gene undergoes rearrangement in a high percentage of osteosarcomas, resulting in loss of its expression. The loss of p53 regulation inhibits further osteocalcin production. The absence of end-point differentiation in bone due to p53 rearrangements and lack of osteocalcin production may contribute to the maintenance of the tumorigenic phenotype in osteosarcomas.